「ida」の検索結果

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Plan and execute reproducible computational research with explicit inputs, environments, provenance, deterministic steps, validation, and workspace outputs. Use for analyses that must be rerun, audited, or handed to another researcher.

日本語の概要は準備中です。原文の説明を表示しています。

Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.

日本語の概要は準備中です。原文の説明を表示しています。

Strategic clinical trial design feasibility assessment. Analyzes 6 dimensions (endpoint, population, comparator, effect size, duration, regulatory pathway) using precedent trials and FDA guidance. Produces enrollment projections, endpoint recommendations, and approval-pathway analysis. Use for trial-protocol design, power/sample-size estimation, comparator selection, and FDA submission strategy. Driven by precedent-based reasoning rather than first-principles math.

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Automated dimensional analysis — Buckingham Pi theorem, non-dimensionalization, unit validation with pint, and characteristic scale estimation. Use before any physics computation to verify consistency and reduce parameter space.

日本語の概要は準備中です。原文の説明を表示しています。

Build training datasets for LLM specialization from production data, frontier model distillation, and synthetic bootstrapping. Use when formatting production logs into SFT data, distilling from frontier APIs, or preparing data for fine-tuning. Covers JSONL formatting, data quality validation, deduplication, and train/eval splitting.

日本語の概要は準備中です。原文の説明を表示しています。

Rigorous methodology for evaluating ML models on established benchmarks. Covers proper train/val/test splits, baseline verification from original papers, exact metric formula discrepancies, data-leak detection checklist, multi-seed robustness, and honest reporting templates. Use when claiming to beat published baselines, writing methods papers, or auditing existing results.

日本語の概要は準備中です。原文の説明を表示しています。

Expert guidance for distributed training with DeepSpeed - ZeRO optimization stages, pipeline parallelism, FP16/BF16/FP8, 1-bit Adam, sparse attention

日本語の概要は準備中です。原文の説明を表示しています。

Expert guidance for GRPO/RL fine-tuning with TRL for reasoning and task-specific model training

日本語の概要は準備中です。原文の説明を表示しています。

Expert guidance for fine-tuning LLMs with LLaMA-Factory - WebUI no-code, 100+ models, 2/3/4/5/6/8-bit QLoRA, multimodal support

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for interpreting and manipulating neural network internals using nnsight with optional NDIF remote execution. Use when needing to run interpretability experiments on massive models (70B+) without local GPU resources, or when working with any PyTorch architecture.

日本語の概要は準備中です。原文の説明を表示しています。

Expert guidance for Fully Sharded Data Parallel training with PyTorch FSDP - parameter sharding, mixed precision, CPU offloading, FSDP2

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for performing causal interventions on PyTorch models using pyvene's declarative intervention framework. Use when conducting causal tracing, activation patching, interchange intervention training, or testing causal hypotheses about model behavior.

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for training and analyzing Sparse Autoencoders (SAEs) using SAELens to decompose neural network activations into interpretable features. Use when discovering interpretable features, analyzing superposition, or studying monosemantic representations in language models.

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for mechanistic interpretability research using TransformerLens to inspect and manipulate transformer internals via HookPoints and activation caching. Use when reverse-engineering model algorithms, studying attention patterns, or performing activation patching experiments.

日本語の概要は準備中です。原文の説明を表示しています。

Hamiltonian mechanics — symplectic integrators (leapfrog, Yoshida), Hamilton's equations, Poisson brackets, canonical transformations, action-angle variables, and KAM theory analysis. Use for energy-conserving long-time integration of conservative systems.

日本語の概要は準備中です。原文の説明を表示しています。

Builds diagnostic and prognostic classifiers on omics feature matrices with regularized logistic regression, random forest, and gradient-boosted trees, handling the p>>n regime, batch shortcut learning, class imbalance, and probability calibration. Use when building a classifier from expression, methylation, or variant data, choosing an algorithm for high-dimensional small-n data, or diagnosing a suspiciously perfect AUC. For unbiased evaluation see machine-learning/model-validation; for feature selection see machine-learning/biomarker-discovery; for time-to-event outcomes see machine-learning/survival-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end neoantigen discovery from somatic variants to ranked vaccine candidates. Integrates HLA typing, MHC binding prediction, pVACtools neoantigen calling, and immunogenicity scoring. Use when identifying tumor neoantigens for personalized vaccine design or checkpoint biomarkers.

日本語の概要は準備中です。原文の説明を表示しています。

Expert guidance for fine-tuning LLMs with Axolotl - YAML configs, 100+ models, LoRA/QLoRA, DPO/KTO/ORPO/GRPO, multimodal support

日本語の概要は準備中です。原文の説明を表示しています。

Explains ML predictions on omics data with SHAP, LIME, and permutation importance, handling the correlated-feature trap, the conditional-vs-interventional Shapley choice, and the attribution-is-not-causation boundary. Use when interpreting an omics classifier, debugging shortcut/batch learning, or deciding whether an attribution ranking can be trusted as biology. For validated feature selection see machine-learning/biomarker-discovery; explanations are not a selection method.

日本語の概要は準備中です。原文の説明を表示しています。

Builds and validates predictive time-to-event models on clinical and omics data with penalized Cox, random survival forests, gradient-boosted and deep survival models, and prediction-grade evaluation (Uno's C, time-dependent AUC, integrated Brier, calibration, competing risks). Use when building an individualized risk predictor or prognostic omics signature, choosing a survival model, or evaluating one beyond the C-index. For Kaplan-Meier, log-rank, and classical Cox hazard-ratio inference in a trial see clinical-biostatistics/survival-analysis.

日本語の概要は準備中です。原文の説明を表示しています。